# Affinity Asset Advisors, LLC

> Institutional holdings reported to the SEC as of Q2 2026 on Form 13F. CIK 1773195. Source: https://holderbook.com/funds/1773195-affinity-asset-advisors-llc/

- Reported value: $2.2B
- Positions: 110
- Weight of the ten largest: 40.6%
- Filed: 2026-08-13

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| ROIVANT SCIENCES LTD | [ROIV](https://holderbook.com/stocks/ROIV/) | $132.7M | 3,750,000 | 6.0% | 6 |
| APOGEE THERAPEUTICS INC | [APGE](https://holderbook.com/stocks/APGE/) | $131.0M | 987,000 | 5.9% | 12 |
| SPYRE THERAPEUTICS INC | [SYRE](https://holderbook.com/stocks/SYRE/) | $113.6M | 1,279,134 | 5.1% | 12 |
| XENON PHARMACEUTICALS INC | [XENE](https://holderbook.com/stocks/XENE/) | $96.3M | 1,595,000 | 4.4% | 15 |
| ERASCA INC | [ERAS](https://holderbook.com/stocks/ERAS/) | $96.2M | 5,250,000 | 4.3% | 9 |
| ALKERMES PLC | [ALKS](https://holderbook.com/stocks/ALKS/) | $72.0M | 1,125,000 | 3.3% | 12 |
| INSMED INC | [INSM](https://holderbook.com/stocks/INSM/) | $69.3M | 650,000 | 3.1% | 9 |
| MODERNA INC | [MRNA](https://holderbook.com/stocks/MRNA/) | $68.3M | 0 | 3.1% | 2 |
| PRAXIS PRECISION MEDICINES I | [PRAX](https://holderbook.com/stocks/PRAX/) | $61.9M | 185,000 | 2.8% | 3 |
| ORUKA THERAPEUTICS INC | [ORKA](https://holderbook.com/stocks/ORKA/) | $56.2M | 590,000 | 2.5% | 8 |
| ANAPTYSBIO INC | [ANAB](https://holderbook.com/stocks/ANAB/) | $55.8M | 826,109 | 2.5% | 3 |
| AVALO THERAPEUTICS INC | [AVTX](https://holderbook.com/stocks/AVTX/) | $53.6M | 2,900,000 | 2.4% | 10 |
| CYTOKINETICS INC | [CYTK](https://holderbook.com/stocks/CYTK/) | $46.9M | 550,000 | 2.1% | 4 |
| REVOLUTION MEDICINES INC | [RVMD](https://holderbook.com/stocks/RVMD/) | $46.8M | 250,000 | 2.1% | 4 |
| ABIVAX SA | [ABVX](https://holderbook.com/stocks/ABVX/) | $44.0M | 330,000 | 2.0% | 6 |
| FIRST TRACKS BIOTHERAPEUTICS | [TRAX](https://holderbook.com/stocks/TRAX/) | $40.9M | 2,032,012 | 1.8% | 1 |
| DIANTHUS THERAPEUTICS INC | [DNTH](https://holderbook.com/stocks/DNTH/) | $39.0M | 400,000 | 1.8% | 4 |
| SUTRO BIOPHARMA INC | [STRO](https://holderbook.com/stocks/STRO/) | $38.9M | 1,172,487 | 1.8% | 3 |
| NUVALENT INC | [NUVL](https://holderbook.com/stocks/NUVL/) | $34.0M | 275,000 | 1.5% | 12 |
| TREVI THERAPEUTICS INC | [TRVI](https://holderbook.com/stocks/TRVI/) | $33.6M | 1,800,172 | 1.5% | 6 |
| ARK ETF TR | [ARKG](https://holderbook.com/stocks/ARKG/) | $31.5M | 0 | 1.4% | 1 |
| OVID THERAPEUTICS INC | [OVID](https://holderbook.com/stocks/OVID/) | $27.3M | 10,144,562 | 1.2% | 6 |
| LEXEO THERAPEUTICS INC | [LXEO](https://holderbook.com/stocks/LXEO/) | $27.0M | 5,807,611 | 1.2% | 6 |
| CELLDEX THERAPEUTICS INC NEW | [CLDX](https://holderbook.com/stocks/CLDX/) | $26.0M | 700,000 | 1.2% | 4 |
| BELITE BIO INC | [BLTE](https://holderbook.com/stocks/BLTE/) | $25.4M | 165,000 | 1.1% | 3 |
| ENLIVEN THERAPEUTICS INC | [ELVN](https://holderbook.com/stocks/ELVN/) | $25.4M | 500,000 | 1.1% | 2 |
| FORTE BIOSCIENCES INC | [FBRX](https://holderbook.com/stocks/FBRX/) | $24.3M | 1,145,391 | 1.1% | 3 |
| ELI LILLY & CO | [LLY](https://holderbook.com/stocks/LLY/) | $24.0M | 0 | 1.1% | 1 |
| NURIX THERAPEUTICS INC | [NRIX](https://holderbook.com/stocks/NRIX/) | $23.5M | 967,620 | 1.1% | 15 |
| ALTO NEUROSCIENCE INC | [ANRO](https://holderbook.com/stocks/ANRO/) | $22.4M | 850,000 | 1.0% | 2 |
| MADRIGAL PHARMACEUTICALS INC | [MDGL](https://holderbook.com/stocks/MDGL/) | $21.5M | 40,000 | 1.0% | 19 |
| PROTAGONIST THERAPEUTICS INC | [PTGX](https://holderbook.com/stocks/PTGX/) | $21.1M | 172,125 | 1.0% | 7 |
| MINERALYS THERAPEUTICS INC | [MLYS](https://holderbook.com/stocks/MLYS/) | $20.2M | 750,000 | 0.9% | 10 |
| RELAY THERAPEUTICS INC | [RLAY](https://holderbook.com/stocks/RLAY/) | $19.6M | 1,050,000 | 0.9% | 2 |
| SAGIMET BIOSCIENCES INC | [SGMT](https://holderbook.com/stocks/SGMT/) | $19.3M | 2,497,864 | 0.9% | 4 |
| JADE BIOSCIENCES INC | [JBIO](https://holderbook.com/stocks/JBIO/) | $18.7M | 840,350 | 0.8% | 5 |
| COGENT BIOSCIENCES INC | [COGT](https://holderbook.com/stocks/COGT/) | $17.4M | 450,000 | 0.8% | 3 |
| UNIQURE NV | [QURE](https://holderbook.com/stocks/QURE/) | $17.3M | 175,000 | 0.8% | 6 |
| TRAVERE THERAPEUTICS INC | [TVTX](https://holderbook.com/stocks/TVTX/) | $17.0M | 300,000 | 0.8% | 7 |
| CULLINAN THERAPEUTICS INC | [CGEM](https://holderbook.com/stocks/CGEM/) | $15.9M | 875,760 | 0.7% | 11 |
| SAVARA INC | [SVRA](https://holderbook.com/stocks/SVRA/) | $15.5M | 2,512,153 | 0.7% | 5 |
| IDEAYA BIOSCIENCES INC | [IDYA](https://holderbook.com/stocks/IDYA/) | $14.9M | 400,000 | 0.7% | 1 |
| PERSPECTIVE THERAPEUTICS INC | [CATX](https://holderbook.com/stocks/CATX/) | $14.4M | 4,214,582 | 0.6% | 9 |
| ODYSSEY THERAPEUTICS INC | [ODTX](https://holderbook.com/stocks/ODTX/) | $14.3M | 766,346 | 0.6% | 1 |
| COGENT BIOSCIENCES INC | - | $13.7M | 11,000,000 | 0.6% | 3 |
| OMEROS CORP | [OMER](https://holderbook.com/stocks/OMER/) | $13.4M | 0 | 0.6% | 1 |
| HELIX ACQUISITION CORP III | [HLXC](https://holderbook.com/stocks/HLXC/) | $13.3M | 1,250,000 | 0.6% | 2 |
| EQUILLIUM INC | [EQ](https://holderbook.com/stocks/EQ/) | $13.1M | 4,100,000 | 0.6% | 2 |
| ESTABLISHMENT LABS HLDGS INC | [ESTA](https://holderbook.com/stocks/ESTA/) | $12.7M | 148,013 | 0.6% | 22 |
| CLIMB BIO INC | [CLYM](https://holderbook.com/stocks/CLYM/) | $12.7M | 972,000 | 0.6% | 9 |
| TEVA PHARMACEUTICAL INDS LTD | [TEVA](https://holderbook.com/stocks/TEVA/) | $12.7M | 374,000 | 0.6% | 13 |
| VERADERMICS INC | [MANE](https://holderbook.com/stocks/MANE/) | $12.3M | 100,000 | 0.6% | 2 |
| ARROWHEAD PHARMACEUTICALS IN | [ARWR](https://holderbook.com/stocks/ARWR/) | $12.2M | 150,000 | 0.6% | 3 |
| OMEROS CORP | - | $12.2M | 6,525,000 | 0.6% | 5 |
| TAYSHA GENE THERAPIES INC | [TSHA](https://holderbook.com/stocks/TSHA/) | $11.9M | 1,750,000 | 0.5% | 5 |
| DAMORA THERAPEUTICS INC | [DMRA](https://holderbook.com/stocks/DMRA/) | $11.1M | 425,000 | 0.5% | 2 |
| EUPRAXIA PHARMACEUTICALS INC | [EPRX](https://holderbook.com/stocks/EPRX/) | $10.9M | 1,650,000 | 0.5% | 4 |
| VERA THERAPEUTICS INC | [VERA](https://holderbook.com/stocks/VERA/) | $10.7M | 250,000 | 0.5% | 10 |
| PROQR THRAPEUTICS N V | [PRQR](https://holderbook.com/stocks/PRQR/) | $10.3M | 5,543,936 | 0.5% | 7 |
| NEWAMSTERDAM PHARMA COMPANY | [NAMS](https://holderbook.com/stocks/NAMS/) | $9.3M | 275,000 | 0.4% | 13 |
| KORRO BIO INC | [KRRO](https://holderbook.com/stocks/KRRO/) | $9.3M | 706,904 | 0.4% | 2 |
| ANTERIS TECHNOLOGIES GLOBAL | [AVR](https://holderbook.com/stocks/AVR/) | $9.0M | 912,397 | 0.4% | 7 |
| ZURA BIO LTD | [ZURA](https://holderbook.com/stocks/ZURA/) | $8.6M | 1,464,303 | 0.4% | 10 |
| ASCENDIS PHARMA A/S | [ASND](https://holderbook.com/stocks/ASND/) | $8.0M | 30,000 | 0.4% | 1 |
| IBIO INC | [IBIO](https://holderbook.com/stocks/IBIO/) | $7.0M | 4,007,881 | 0.3% | 3 |
| GENERATE BIOMEDICINES INC | [GENB](https://holderbook.com/stocks/GENB/) | $6.7M | 400,000 | 0.3% | 2 |
| EVOMMUNE INC | [EVMN](https://holderbook.com/stocks/EVMN/) | $6.6M | 0 | 0.3% | 1 |
| TYRA BIOSCIENCES INC | [TYRA](https://holderbook.com/stocks/TYRA/) | $6.4M | 200,012 | 0.3% | 2 |
| SOL-GEL TECHNOLOGIES LTD | [SLGL](https://holderbook.com/stocks/SLGL/) | $6.3M | 84,900 | 0.3% | 2 |
| SAB BIOTHERAPEUTICS INC | [SABS](https://holderbook.com/stocks/SABS/) | $5.9M | 1,525,000 | 0.3% | 2 |
| MACROGENICS INC | [MGNX](https://holderbook.com/stocks/MGNX/) | $5.6M | 1,216,606 | 0.3% | 3 |
| CRISPR THERAPEUTICS AG | [CRSP](https://holderbook.com/stocks/CRSP/) | $5.5M | 100,000 | 0.2% | 2 |
| NEWAMSTERDAM PHARMA COMPANY | [NAMSW](https://holderbook.com/stocks/NAMSW/) | $5.3M | 245,000 | 0.2% | 14 |
| ASSEMBLY BIOSCIENCES INC | [ASMB](https://holderbook.com/stocks/ASMB/) | $5.2M | 190,000 | 0.2% | 1 |
| REZOLUTE INC | [RZLT](https://holderbook.com/stocks/RZLT/) | $5.2M | 1,000,000 | 0.2% | 10 |
| PRECISION BIOSCIENCES INC | [DTIL](https://holderbook.com/stocks/DTIL/) | $5.1M | 646,576 | 0.2% | 2 |
| HEMAB THERAPEUTICS HLDGS INC | - | $5.1M | 138,030 | 0.2% | 1 |
| VIRIDIAN THERAPEUTICS INC | [VRDN](https://holderbook.com/stocks/VRDN/) | $4.6M | 250,000 | 0.2% | 9 |
| ARRIVENT BIOPHARMA INC | [AVBP](https://holderbook.com/stocks/AVBP/) | $4.3M | 125,000 | 0.2% | 3 |
| VERRICA PHARMACEUTICALS INC | [VRCA](https://holderbook.com/stocks/VRCA/) | $4.3M | 707,338 | 0.2% | 3 |
| COMPASS PATHWAYS PLC | [CMPS](https://holderbook.com/stocks/CMPS/) | $4.3M | 301,183 | 0.2% | 4 |
| MBX BIOSCIENCES INC | [MBX](https://holderbook.com/stocks/MBX/) | $4.1M | 75,000 | 0.2% | 4 |
| RESEARCH ALLIANCE CORP III | [RACC](https://holderbook.com/stocks/RACC/) | $4.0M | 370,000 | 0.2% | 1 |
| IMMUNOVANT INC | [IMVT](https://holderbook.com/stocks/IMVT/) | $3.9M | 100,000 | 0.2% | 4 |
| AMANAT ACQUISITION CORP | [AMAN](https://holderbook.com/stocks/AMAN/) | $3.8M | 375,000 | 0.2% | 1 |
| BIOHAVEN LTD | [BHVN](https://holderbook.com/stocks/BHVN/) | $3.7M | 250,000 | 0.2% | 1 |
| FAETH THERAPEUTICS INC | [FTH](https://holderbook.com/stocks/FTH/) | $3.6M | 144,404 | 0.2% | 1 |
| KARYOPHARM THERAPEUTICS INC | [KPTI](https://holderbook.com/stocks/KPTI/) | $3.1M | 312,500 | 0.1% | 5 |
| ALECTOR INC | [ALEC](https://holderbook.com/stocks/ALEC/) | $3.0M | 1,510,000 | 0.1% | 2 |
| SPYGLASS PHARMA INC | [SGP](https://holderbook.com/stocks/SGP/) | $2.9M | 131,586 | 0.1% | 2 |
| CRINETICS PHARMACEUTICALS IN | [CRNX](https://holderbook.com/stocks/CRNX/) | $2.8M | 75,000 | 0.1% | 12 |
| OAKTREE ACQUISITION CORP III | [OACCU](https://holderbook.com/stocks/OACCU/) | $2.8M | 250,000 | 0.1% | 7 |
| CELCUITY INC | - | $2.3M | 2,000,000 | 0.1% | 1 |
| JATT II ACQUISITION CORP | - | $2.3M | 200,000 | 0.1% | 1 |
| NEUMORA THERAPEUTICS INC. | [NMRA](https://holderbook.com/stocks/NMRA/) | $1.8M | 1,070,651 | 0.1% | 1 |
| AMYLYX PHARMACEUTICALS INC | [AMLX](https://holderbook.com/stocks/AMLX/) | $1.8M | 98,999 | 0.1% | 1 |
| ADLAI NORTYE LTD | [ANL](https://holderbook.com/stocks/ANL/) | $1.8M | 153,847 | 0.1% | 2 |
| SPRUCE BIOSCIENCES INC | [SPRB](https://holderbook.com/stocks/SPRB/) | $1.6M | 30,000 | 0.1% | 1 |
| SUMMIT THERAPEUTICS INC | [SMMT](https://holderbook.com/stocks/SMMT/) | $1.5M | 0 | 0.1% | 1 |
| EIKON THERAPEUTICS INC | [EIKN](https://holderbook.com/stocks/EIKN/) | $1.3M | 98,001 | 0.1% | 1 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q2 2026 | +22.3% | +14.8% | +7.4% | 90% |
| Q1 2026 | +10.5% | -4.6% | +15.2% | 88% |
| Q4 2025 | +29.0% | +2.4% | +26.6% | 88% |
| Q3 2025 | +31.5% | +7.8% | +23.7% | 95% |
| Q2 2025 | +8.3% | +10.5% | -2.2% | 68% |
| Q1 2025 | -16.1% | -4.6% | -11.6% | 92% |
| Q4 2024 | -6.6% | +2.1% | -8.8% | 90% |
| Q3 2024 | +13.1% | +5.4% | +7.6% | 82% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q2 2026 | $2.2B | 110 |
| Q1 2026 | $1.9B | 103 |
| Q4 2025 | $1.8B | 92 |
| Q3 2025 | $1.1B | 93 |
| Q2 2025 | $732.2M | 88 |
| Q1 2025 | $1.0B | 91 |
| Q4 2024 | $746.0M | 83 |
| Q3 2024 | $732.8M | 84 |
| Q2 2024 | $867.5M | 91 |
| Q1 2024 | $807.8M | 89 |
| Q4 2023 | $547.5M | 76 |
| Q3 2023 | $355.5M | 74 |